Effects of tibolone on abdominal subcutaneous fat, serum leptin levels, and anthropometric indices: a 6-month, prospective, randomized, placebo-controlled, double-blind study

• Published in: Advances in therapy 2006-11, Vol.23 (6), p.926-937
• Main Authors: Odabasi, Ali Riza, Yuksel, Hasan, Kafkas, Samet, Demircan, Selda, Karul, Aslihan, Kozaci, Didem, Koseoglu, Kutsi, Onur, Ergun
• Format: Article
• Language: English
• Subjects: Adipose Tissue - drug effects; Adult; Aged; Body Weights and Measures; Double-Blind Method; Estrogen Receptor Modulators - therapeutic use; Female; Health technology assessment; Humans; Leptin - blood; Middle Aged; Norpregnenes - therapeutic use; Postmenopause; Prospective Studies
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/BF02850215

This study was undertaken to evaluate the effects of tibolone on abdominal subcutaneous fat, serum leptin levels (SLLs), and anthropometric indices, and to investigate potential relationships between SLLs, subcutaneous abdominal fat thickness, and anthropometric indices in postmenopausal women. In a 6-mo, prospective, randomized, double-blind, placebo-controlled study, 40 healthy postmenopausal women aged 42 to 67 y (mean: 50+/-4.7 y) were randomly assigned to 1 of 2 groups; during a 6-mo treatment period, the first group received tibolone (Livial tablet; Organon, The Netherlands; 2.5 mg/d; n=19) and the other group was given placebo (n=21). Fasting SLLs determined by enzyme-linked immunosorbent assay, subcutaneous abdominal fat thickness assessed by ultrasound, and anthropometric indices of body weight, body mass index, waist and hip circumference, and waist-to-hip ratio (WHR) were recorded at the beginning and the end of the study. Statistical analyses were performed with Mann-Whitney, Wilcoxon, and Spearman tests. P values